Phase II Study to Evaluate the Efficacy and Tolerability of Intravesical Vicinium in Patients With Non-Invasive Urothelial Carcinoma in Situ (CIS) Previously Treated With Bacille Calmette-Guerin (BCG)
Phase of Trial: Phase II
Latest Information Update: 02 Jul 2015
At a glance
- Drugs Oportuzumab monatox (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- Sponsors Viventia Biotechnologies
- 02 Jul 2015 According to Viventia Biotechnologies media release, clinical results were published in the Journal of Urology.
- 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Dec 2009 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.